Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...

Merck is in talks to buy cancer drug developer Revolution Medicines, the Financial Times reported on Thursday, citing people ...

Merck & Co. is in talks to acquire the cancer-focused biotech company Revolution Medicines Inc., according to a report in the ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best DOW Stocks to Buy in 2026. On January 5, Wells Fargo added Merck & ...

Rising shares of Merck & Co. and Boeing Co. were helping turn around the Dow Jones Industrial Average in early trading. Drugmaker Merck saw its shares gain 2.5%, leading the blue-chip index higher ...